Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$63.20
+23.1%
$52.36
$43.38
$65.74
$8.56B1.111.15 million shs4.37 million shs
Haemonetics Co. stock logo
HAE
Haemonetics
$93.18
-2.1%
$83.22
$70.74
$97.13
$4.73B0.34452,604 shs369,703 shs
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$24.78
-1.2%
$32.95
$22.36
$50.78
$1.95B1.17809,938 shs762,266 shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
Penumbra, Inc. stock logo
PEN
Penumbra
$202.01
-3.8%
$221.64
$180.93
$348.67
$7.83B0.57348,158 shs499,206 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
+2.17%+3.15%-0.91%-2.84%-11.71%
Haemonetics Co. stock logo
HAE
Haemonetics
-0.21%+3.37%+12.40%+23.36%+16.29%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
+8.38%-14.02%-26.24%-39.10%-50.21%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-6.62%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.77%+6.96%-6.23%-20.84%-32.41%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.8817 of 5 stars
3.32.00.04.13.14.23.1
Haemonetics Co. stock logo
HAE
Haemonetics
4.0461 of 5 stars
2.32.00.04.32.71.72.5
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
4.9455 of 5 stars
4.03.00.04.02.81.73.8
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
4.852 of 5 stars
4.41.00.03.82.42.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.67
Moderate Buy$67.006.01% Upside
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6712.33% Upside
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
2.00
Hold$36.8048.51% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.78
Moderate Buy$304.4550.71% Upside

Current Analyst Ratings

Latest GMED, PEN, IART, HAE, and NUVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$55.00 ➝ $60.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $63.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$64.00 ➝ $70.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/8/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$290.00 ➝ $260.00
5/8/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$37.00 ➝ $24.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$49.00 ➝ $40.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$37.00 ➝ $25.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$42.00 ➝ $26.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.02B8.39$4.39 per share14.40$29.32 per share2.16
Haemonetics Co. stock logo
HAE
Haemonetics
$1.27B3.73$4.91 per share18.98$16.22 per share5.74
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$1.54B1.26$4.14 per share5.98$20.31 per share1.22
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06B7.40$2.74 per share73.75$30.55 per share6.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$122.87M$1.1754.0219.271.537.83%8.82%7.20%8/1/2024 (Estimated)
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4637.8821.982.239.97%22.37%9.71%5/9/2024 (Confirmed)
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$67.74M$0.8329.866.860.874.39%15.19%6.59%7/24/2024 (Estimated)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$2.3187.4550.762.068.59%7.49%5.60%8/6/2024 (Estimated)

Latest GMED, PEN, IART, HAE, and NUVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/7/2024Q1 2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.55$0.72+$0.17$1.49$586.82 million$606.67 million    
5/7/2024Q1 2024
Penumbra, Inc. stock logo
PEN
Penumbra
$0.42$0.41-$0.01$0.54$274.94 million$278.70 million      
5/6/2024Q1 2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.55$0.55N/A$1.14$361.96 million$368.90 million    
2/28/202412/31/2023
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.90$0.89-$0.01$1.53$399.30 million$397.00 million    
2/22/2024Q4 2023
Penumbra, Inc. stock logo
PEN
Penumbra
$0.71$0.76+$0.05$0.14$286.62 million$284.68 million      
2/20/2024Q4 2023
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.59$0.60+$0.01$1.09$608.21 million$616.53 million    
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.10
4.88
2.72
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
0.94
3.45
2.18
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.06
3.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
84.78%
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
24.30%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3.10%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,000135.37 million102.48 millionOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3,94678.60 million76.17 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.76 million36.82 millionOptionable

GMED, PEN, IART, HAE, and NUVA Headlines

SourceHeadline
Penumbra (NYSE:PEN) Price Target Cut to $260.00 by Analysts at Piper SandlerPenumbra (NYSE:PEN) Price Target Cut to $260.00 by Analysts at Piper Sandler
marketbeat.com - May 8 at 1:09 PM
Penumbra (PEN) Q1 Earnings Lag Estimates, Margins ExpandPenumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand
zacks.com - May 8 at 11:46 AM
The Latest Analyst Ratings For PenumbraThe Latest Analyst Ratings For Penumbra
markets.businessinsider.com - May 8 at 11:06 AM
Buy Rating Affirmed for Penumbra on Strong Q1 Performance and Robust Growth ProspectsBuy Rating Affirmed for Penumbra on Strong Q1 Performance and Robust Growth Prospects
markets.businessinsider.com - May 8 at 11:06 AM
Penumbra (NYSE:PEN) Rating Reiterated by Needham & Company LLCPenumbra (NYSE:PEN) Rating Reiterated by Needham & Company LLC
marketbeat.com - May 8 at 9:35 AM
PEN Stock Earnings: Penumbra Beats EPS, Beats Revenue for Q1 2024PEN Stock Earnings: Penumbra Beats EPS, Beats Revenue for Q1 2024
msn.com - May 8 at 1:05 AM
Penumbra Inc (PEN) Surpasses Analyst Revenue Forecasts in Q1 2024Penumbra Inc (PEN) Surpasses Analyst Revenue Forecasts in Q1 2024
finance.yahoo.com - May 7 at 8:04 PM
Penumbra, Inc. Reports First Quarter 2024 Financial ResultsPenumbra, Inc. Reports First Quarter 2024 Financial Results
prnewswire.com - May 7 at 4:05 PM
Penumbra Q1 2024 Earnings PreviewPenumbra Q1 2024 Earnings Preview
msn.com - May 6 at 9:34 PM
Dont Overlook These Top Medical Stocks as Q1 Earnings ApproachDon't Overlook These Top Medical Stocks as Q1 Earnings Approach
zacks.com - May 6 at 9:01 PM
Summit Trail Advisors LLC Invests $1.35 Million in Penumbra, Inc. (NYSE:PEN)Summit Trail Advisors LLC Invests $1.35 Million in Penumbra, Inc. (NYSE:PEN)
marketbeat.com - May 6 at 7:26 PM
Penumbra is about to announce its earnings — heres what to expectPenumbra is about to announce its earnings — here's what to expect
markets.businessinsider.com - May 6 at 9:54 AM
Neurovascular Intervention Devices Market Projected to Reach $6.21 billion by 2030 - Exclusive Report by 360iResearchNeurovascular Intervention Devices Market Projected to Reach $6.21 billion by 2030 - Exclusive Report by 360iResearch
prnewswire.co.uk - May 2 at 1:13 PM
Alameda Chamber Recognizes Excellent Businesses, LeadersAlameda Chamber Recognizes Excellent Businesses, Leaders
msn.com - May 2 at 8:12 AM
Hush money lawyer warned he could be disbarred for following Trumps ordersHush money lawyer warned he could be disbarred for following Trump's orders
msn.com - May 2 at 8:12 AM
Horrors from Above: Eclipses, Comets, and Human DreadHorrors from Above: Eclipses, Comets, and Human Dread
psychologytoday.com - May 2 at 8:12 AM
Any Lawyer Who Followed Trump’s Advice Would End Up in JailAny Lawyer Who Followed Trump’s Advice Would End Up in Jail
thedailybeast.com - May 2 at 8:12 AM
Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare ConferencePenumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference
prnewswire.com - May 1 at 4:05 PM
New York State Common Retirement Fund Purchases 6,152 Shares of Penumbra, Inc. (NYSE:PEN)New York State Common Retirement Fund Purchases 6,152 Shares of Penumbra, Inc. (NYSE:PEN)
marketbeat.com - April 30 at 5:45 AM
Penumbra (PEN) Set to Announce Quarterly Earnings on TuesdayPenumbra (PEN) Set to Announce Quarterly Earnings on Tuesday
americanbankingnews.com - April 30 at 4:34 AM
Critics at Odds Over the Polarizing Finale of “Queen Of Tears”Critics at Odds Over the Polarizing Finale of “Queen Of Tears”
msn.com - April 30 at 2:39 AM
Global Blood Clot Retrieval Devices Market Projected to Surge to US$ 5.7 Billion by 2032Global Blood Clot Retrieval Devices Market Projected to Surge to US$ 5.7 Billion by 2032
fmiblog.com - April 30 at 2:39 AM
Philly restaurateur Tracey Syphax found success after prisonPhilly restaurateur Tracey Syphax found success after prison
msn.com - April 30 at 2:39 AM
Review: ‘Illinoise’ puts movement to the music of Sufjan Stevens — it’s not the usual Broadway showReview: ‘Illinoise’ puts movement to the music of Sufjan Stevens — it’s not the usual Broadway show
msn.com - April 29 at 8:53 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Globus Medical logo

Globus Medical

NYSE:GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Integra LifeSciences logo

Integra LifeSciences

NASDAQ:IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.
Penumbra logo

Penumbra

NYSE:PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.